The Role of Intratumoral Therapy With Cisplatin/Epinephrine Injectable Gel in the Management of Advanced Squamous Cell Carcinoma of the Head and Neck

Wenig, Barry L.; Werner, Jochen A.; Castro, Dan J.; Sridhar, Kasi S.; Garewal, Harinder S.; Kehrl, W.; Płużańska, A; Arndt, Olaf; Costantino, Peter D.; Mills, Glenn; Dunphy, Frank; Orenberg, Elaine K.; Leavitt, Richard D.

doi:10.1001/archotol.128.8.880

Cited by 37 publications

(16 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, there are several obstacles to the successful implementation of i.t. administration of antitumor agents using injectable polymer depots: (1) macromolecules and nanoparticles can not effectively distribute across the tumor by diffusion, which limits interstitial penetration [16]; (2) rapid clearance of soluble polymers and drugs from the tumor interstitium [17]; (3) dose-limiting normal-tissue toxicity arising from proximal drug diffusion outside the region of interest; and (4) distal normal-tissue toxicity caused by systemic re-absorption [18–21]. …”

Section: Introductionmentioning

confidence: 99%

Injectable intratumoral depot of thermally responsive polypeptide–radionuclide conjugates delays tumor progression in a mouse model

Liu

MacKay

Dreher

et al. 2010

Journal of Controlled Release

View full text Add to dashboard Cite

This study evaluated a biodegradable drug delivery system for local cancer radiotherapy consisting of a thermally sensitive elastin-like polypeptide (ELP) conjugated to a therapeutic radionuclide. Two ELPs (49 kD) were synthesized using genetic engineering to test the hypothesis that injectable biopolymeric depots can retain radionuclides locally and reduce the growth of tumors. A thermally sensitive polypeptide, ELP 1 , was designed to spontaneously undergo a soluble-insoluble phase transition (forming viscous microparticles) between room temperature and body temperature upon intratumoral injection, while ELP 2 was designed to remain soluble upon injection and to serve as a negative control for the effect of aggregate assembly. After intratumoral administration of radionuclide conjugates of ELPs into implanted tumor xenografts in nude mice, their retention within the tumor, spatio-temporal distribution, and therapeutic effect were quantified. The residence time of the radionuclide-ELP 1 in the tumor was significantly longer than the thermally insensitive ELP 2 conjugate. In addition, the thermal transition of ELP 1 significantly protected the conjugated radionuclide from dehalogenation, whereas the conjugated radionuclide on ELP 2 was quickly eliminated from the tumor and cleaved from the biopolymer. These attributes of the thermally sensitive ELP 1 depot improved the antitumor efficacy of iodine-131 compared to the soluble ELP 2 control. This novel injectable and biodegradable depot has the potential to control advanced-stage cancers by reducing the bulk of inoperable tumors, enabling surgical removal of de-bulked tumors, and preserving healthy tissues.

show abstract

Section: Introductionmentioning

confidence: 99%

Injectable intratumoral depot of thermally responsive polypeptide–radionuclide conjugates delays tumor progression in a mouse model

Liu

MacKay

Dreher

et al. 2010

Journal of Controlled Release

View full text Add to dashboard Cite

show abstract

“…Since intratumoral injection is a widely-adopted route of administration in clinic for treating head and neck cancer patient [40–43], to maximize the therapeutic effect of the treatment, free DOX, PLGA/PD-C, DOX@PLGA/PD, and DOX@PLGA/PD-C nanoparticles were administered intratumorally. The thermal images shown in Figure 5A indicated that EGFR targeted PLGA/PD could quickly elevate the temperature of tumor tissue to 55 °C within 2 min.…”

Section: Resultsmentioning

confidence: 99%

Mussel-inspired PLGA/polydopamine core-shell nanoparticle for light induced cancer thermochemotherapy

Markoutsa

Zhan

et al. 2017

Acta Biomaterialia

View full text Add to dashboard Cite

Most photothermal converting systems are not biodegradable, which bring the uneasiness when they are administered into human body due to the uncertainty of their fate. Hereby, we developed a mussel-inspired PLGA/polydopamine core-shell nanoparticle for cancer photothermal and chemotherapy. With the help of an anti-EGFR antibody, the nanoparticle could effectively enter head and neck cancer cells and convert near-infrared light to heat to trigger drug release from PLGA core for chemotherapy as well as ablate tumors by the elevated temperature. Due to the unique nanoparticle concentration dependent peak working-temperature nature, an overheating or overburn situation can be easily prevented. Since the nanoparticle was retained in the tumor tissue and subsequently released its payload inside the cancer cells, no any doxorubicin-associated side effects were detected. Thus, the developed mussel-inspired PLGA/polydopamine core-shell nanoparticle could be a safe and effective tool for the treatment of head and neck cancer.

show abstract

“…Four study overviews, each comprising pooled data from at least 2 RCTs, were identified [10][11][12][13]: the first evaluated data from two trials, in which neoadjuvant chemotherapy or standard radiotherapy was compared with alternating chemoradiotherapy (based on bleomycin/leucovorin/methotrexate/vinblastine or cisplatin/ 5-fluorouracil) [10]; the second assessed data from two trials, in which standard radiotherapy was compared with either concurrent chemoradiotherapy (based on carboplatin/5-fluorouracil) or accelerated radiotherapy [11]; the third provided a weighted median survival analysis of 11 studies of neoadjuvant chemotherapy versus control therapy [12]; and the fourth evaluated data from two trials, in which the safety and efficacy of cisplatin/ epinephrine injectable gel was compared with that of placebo gel in locally recurrent disease [13] (Table 2).…”

Section: Resultsmentioning

confidence: 99%

“…Similarly, large-scale overviews [10,11] and recent RCTs [14][15][16] confirm the clinical benefits of alternating or concurrent chemoradiotherapy regimens, in which platinum-based therapy is used alone or in combination with 5-fluorouracil. A recent overview also highlights a promising future place in HNSCC therapy for cisplatin/epinephrine intratumoral gel in recurrent disease [13].…”

Section: Resultsmentioning

confidence: 99%

Standard, and novel cytotoxic and molecular-targeted, therapies for HNSCC: an evidence-based review

Murdoch

2007

Current Opinion in Oncology

View full text Add to dashboard Cite

(1) Head and neck squamous cell carcinoma is the sixth most frequently occurring cancer worldwide.(2) Chemotherapy has shown some success as part of multimodal treatment schedules for locally advanced, nonmetastatic head and neck squamous cell carcinoma, and too a much lesser extent for metastatic head and neck squamous cell carcinoma.(3) A recent meta-analysis of 32 studies involving >10,000 patients concluded that chemotherapy added to radiotherapy produces a large survival advantage relative to radiotherapy alone.(4) Concurrent or alternate chemoradiotherapy, with a schedule based on cisplatin, has an established place in the management of locally advanced nonmetastatic head and neck squamous cell carcinoma.

show abstract

The Role of Intratumoral Therapy With Cisplatin/Epinephrine Injectable Gel in the Management of Advanced Squamous Cell Carcinoma of the Head and Neck

Abstract: Cisplatin/epinephrine injectable gel reduces tumor burden, ameliorates tumor symptoms, and provides a new therapeutic option for treating patients with squamous cell carcinoma of the head and neck.

Cited by 37 publications

References 14 publications

Injectable intratumoral depot of thermally responsive polypeptide–radionuclide conjugates delays tumor progression in a mouse model

Injectable intratumoral depot of thermally responsive polypeptide–radionuclide conjugates delays tumor progression in a mouse model

Mussel-inspired PLGA/polydopamine core-shell nanoparticle for light induced cancer thermochemotherapy

Standard, and novel cytotoxic and molecular-targeted, therapies for HNSCC: an evidence-based review

Contact Info

Product

Resources

About